Jeena Sikho Lifecare Q1 FY27 Earnings Call Transcript Released
Jeena Sikho Lifecare released its Q1 FY27 earnings call transcript. The company reported Q1 FY27 revenue of ₹224 crore, EBITDA of ₹92 crore, and PAT of ₹65 crore, with 41% EBITDA and 28% PAT margins. Revenue grew 29% YoY, supported by a 47% YoY growth in the product business and 13% in services. Management reiterated a long-term vision for ₹3000 crore turnover and 7000-10000 beds.
The announcement is a transcript of an earnings call, which provides detailed financial performance and future outlook. While positive, it does not introduce new material events or changes in strategy that would significantly alter the company's immediate trajectory.
The company reported strong year-on-year financial performance with significant revenue and profit growth, along with healthy margins. Management expressed confidence in their long-term strategy and growth prospects, indicating positive future outlook.
Jeena Sikho Lifecare Limited has made available the transcript of their Earnings Conference Call held on August 10, 2026, to discuss the Unaudited Financial Results for the quarter ended June 30, 2026 (Q1 FY27).
During the call, Managing Director Manish Grover emphasized the company's philosophy of focusing on prevention and healthspan rather than just lifespan, detailing their integrated business model that encompasses health awareness, consultations, lifestyle coaching, products, and intensive treatments through hospitals and wellness IPDs. He highlighted that services and products are mutually beneficial, driving engagement and demand for each other. The company reported strong Q1 FY27 financial performance with revenue from operations at ₹224 crore, EBITDA at ₹92 crore, and PAT at ₹65 crore, achieving 41% EBITDA margin and 28% PAT margin.
Mr. Grover also outlined the company's next phase, focusing on technological integration in preventive healthcare and a long-term vision to build a comprehensive health operating system. He reiterated the focus on year-on-year growth, projecting a turnover of ₹3000 crore and 7000-10000 beds in the next 3-5 years with a 30% year-on-year growth target.
Chief Financial Officer Nanak Chand provided further financial details, stating that revenue from operations grew by 29% year-on-year in Q1 FY27, with EBITDA growing 17% YoY and maintaining a 41% EBITDA margin. The Ayurveda healthcare service business saw a 13% growth in Panchakarma revenue, supported by a 33% YoY increase in IPD patients and a 31% increase in day care volume. The Ayurveda healthcare product business grew by 47% YoY.
Discussions also covered the company's strategy to reduce government business due to payment delays, focus on private business growth, and expansion into ultra-luxury wellness centers. The management addressed investor queries regarding quarter-on-quarter performance, advertising expenses, product vs. service focus, and the impact of one-off expenses and new initiatives like Ayushman Yojana.
What to do with a filing like this
Jeena Sikho Lifecare Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Jeena Sikho Lifecare Limited. Read the original for the full detail.